FDA Publishes REMS Assessment Guidance
The guidance describes how to develop a REMS Assessment Plan, discusses the impact of REMS on patient access to drugs, and gives recommendations on reporting REMS findings to FDA.
On January 24, 2019, FDA published guidance on the planning and reporting of the assessment of risk evaluation and mitigation strategies (REMS) for drugs and biologics. The development of a REMS Assessment Plan including the impact on the selection of metrics and data sources is discussed. Also discussed in the guidance are considerations for assessing REMS impact on patient access to drugs and recommendations on reporting REMS findings to FDA.
Specifically, the guidance covers assessment categories, selecting metrics and sources of assessment data, and thresholds for REMS effectiveness. The guidance does not discuss the design or development of REMS.
Source: FDA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
